1. Home
  2. SKYE vs BYM Comparison

SKYE vs BYM Comparison

Compare SKYE & BYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • BYM
  • Stock Information
  • Founded
  • SKYE 2012
  • BYM 2002
  • Country
  • SKYE United States
  • BYM United States
  • Employees
  • SKYE N/A
  • BYM N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • BYM Investment Managers
  • Sector
  • SKYE Health Care
  • BYM Finance
  • Exchange
  • SKYE Nasdaq
  • BYM Nasdaq
  • Market Cap
  • SKYE 294.2M
  • BYM 288.3M
  • IPO Year
  • SKYE N/A
  • BYM N/A
  • Fundamental
  • Price
  • SKYE $6.56
  • BYM $11.67
  • Analyst Decision
  • SKYE Strong Buy
  • BYM
  • Analyst Count
  • SKYE 4
  • BYM 0
  • Target Price
  • SKYE $19.25
  • BYM N/A
  • AVG Volume (30 Days)
  • SKYE 428.5K
  • BYM 60.2K
  • Earning Date
  • SKYE 01-01-0001
  • BYM 01-01-0001
  • Dividend Yield
  • SKYE N/A
  • BYM 4.49%
  • EPS Growth
  • SKYE N/A
  • BYM N/A
  • EPS
  • SKYE N/A
  • BYM N/A
  • Revenue
  • SKYE N/A
  • BYM N/A
  • Revenue This Year
  • SKYE N/A
  • BYM N/A
  • Revenue Next Year
  • SKYE N/A
  • BYM N/A
  • P/E Ratio
  • SKYE N/A
  • BYM N/A
  • Revenue Growth
  • SKYE N/A
  • BYM N/A
  • 52 Week Low
  • SKYE $1.44
  • BYM $9.30
  • 52 Week High
  • SKYE $19.41
  • BYM $11.77
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 38.55
  • BYM 66.09
  • Support Level
  • SKYE $5.48
  • BYM $11.37
  • Resistance Level
  • SKYE $6.93
  • BYM $11.56
  • Average True Range (ATR)
  • SKYE 1.01
  • BYM 0.07
  • MACD
  • SKYE -0.01
  • BYM 0.00
  • Stochastic Oscillator
  • SKYE 46.71
  • BYM 100.00

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About BYM Blackrock Municipal Income Quality Trust of Beneficial Interest

Blackrock Municipal Income Quality Trust is a closed-end municipal bond fund. Its investment objective is to provide current income exempt from U.S. federal income taxes, including the alternative minimum tax. It trust invests in various sectors such as transportation, utilities, health, education, corporate, housing and others.

Share on Social Networks: